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 To investigate the kinetic profile (Absorption , distribution , and excretion )  
of intraperitoneal injected  Ag NPs (24.52 nm ) and ZnO NPs (25.16 nm)  in 
Albino mice  , a single dose of the two kinds of NPs (100 mg/kg)  were used 
for comparison .Kinetic profile in blood clarified  shorter time ( T max ) were 
spend by ZnO NPs to be absorbed compared with longer one recorded by Ag 
NPs as their smaller volume of distribution (Vd) to confirm their higher 
concentration (C max ) with 95 µg/ml compared with Ag NPs which stands on 
57.5 µg/ml  , also Ag NPs needs longer time of elimination to their half values 
(t1/2 Elem.) in blood with lower clearance rate (CL) compared with ZnO NPs 
. This study discussed the distribution profile in different organs over time and 
pointed a considerable Ag and Zn concentrations specially in liver , spleen , 
intestine and kidney, also an important levels recorded in lung ,heart , testes 
and brain. Ag and ZnO NPs excretion manner noted a significant percentage 
of excretion  via feces  with 33 % and 83%for Ag NPs and ZnO NPs 
respectively  compared with small percentage recorded with urine .  
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1. Introduction 
Nano industry has been described as the next industrial revolution as turning to be one of the fastest growing 
industries in the history of human beings [1] with expanding nanotechnology scope in continuous manner as 
using of nano materials in many implementations in our daily life [2]. Nanoparticles are defined as one or 
more dimension small objects in range of 1–100 nm. Due to their small size and large- scale surface area 
compared with micro scale , different degrees of biological toxic effects  were demonstrated by large numbers 
of studies [3]-[6]. Silver nanoparticles (Ag NPs) with mean annual production of 55 tons, individually  
represent the highest used in  many consumer products with the widely expansion in NPs commerce which are 
used as antimicrobial agent in different consumer products with range from clothing, cosmetics, shoes, 
respirators surface coating, detergents, water filters and house purification systems, laptops, and phones [7] . 
Among metal containing nanoparticles , zinc oxide (ZnO NPs) was the third highest production over the world 
with 550 tons, widely used in cosmetic products as UV light scatter specially in sun screens , and dermal 
ointments, and toothpastes [8]. ZnO NPs mostly used in solar cells production and LCDs pigments, 
electronics, rubber, textiles and chemical fiber production [9],[10]. Due to the high surface-to-volume ratio, 
greater oxidant capacity and bio persistence, nanoparticles became the primary source for toxicity, which can 
penetrate easily through epithelium and reach to interstitial pulmonary area. There are real needs to protect our 
public and environmental health and safety, specially where  the standards or guidelines that can directly rule 
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nano materials effects are not exist in present time [11]. However, the tunable and varied physicochemical 
properties of Nanoparticles pose a new challenge for understanding their biological behavior, and bio 
distribution, so the in vivo and in vitro kinetics can be controlled to meet the requirements of efficient drug 
delivery and minimizing side-effects. In vivo porticokinetics refers to the absorption, distribution, metabolism, 
and excretion (ADME) of nanomaterials. the wide definition for Toxicikinetics described by [12] as the 
movement and fate, also referred to as the disposition, of toxicants. The term is most commonly used when 
describing the time course of absorption, distribution, and elimination (including biotransformation and 
excretion) of toxicants in an organism. blood concentrations analysis against time course after single dose 
administration of Ag NPs and ZnO NPs was efficient method for evaluate the amount of absorption and 
quantitative the availability, and helps in evaluation the amount of distribution  and elimination steps [13]. 
Many studies  described kinetic behavior of Ag and ZnO NPs followed  oral or intravenous administration  
[14]-[17] and Only single study demonstrated the biodistribution of ZnO NPs over 27 h followed 
intraperitoneal injection. But no occurred any study demonstrate and analyze the kinetic parameters and 
behaves of NPs followed intraperetoneal injection of Ag or ZnO NPs in mice at world level, in addition  to the 
comparison between them.  
2. Materials and Methods 
2.1. Nanoparticles 
Un coated Ag NPs (20 nm as the specification sheet ) were purchased as grey to black nano powder from 
NANOSHEL company - USA , with purity of 99 % , 10.5 g/cm3 density , and spherical morphology . ZnO 
NPs (10-30 nm as the specification sheet ) were purchased as white to light yellow nano powder from 
Skyspring Nanomaterials incorporation –USA, with purity of 99.8%, 5.606 g/cm3 density and spherical 
morphology. Ag and ZnO NPs  were characterized using scanning probe microscope (SPM) from FILIPS- 
Germany to determine size average for the two kinds of nanoparticles that used in this study. The surface 
morphology of the Ag NPs and ZnO NPs were displayed  by atomic force microscope (AFM) under normal 
atmospheric conditions. The examined samples of nanoparticles were dispersed on glass slide and explored 
using the instrument. 
 
2.2. Animals housing 
Healthy adult male (8-10 week aged) Swiss albino mice with average weight 25±2 gm were purchased from 
the national center for drug control and research  – Ministry of Health. All mice were housed in polypropylene 
cages under controlled conditions of temperature 25 ± 5°C , humidity of 50-60 % , and 12 ± 2 hours light/dark 
cycles. Standard diet pellet and water ad libitum were  used for feeding . The animals were kept for 7 days 
before starting the experiments for acclimatization to laboratory conditions. All animals were dealt in 
accordance to the guidelines of the Care and Use of Laboratory Animals- National Research Council and in 
accordance with the guidelines of the international guidelines for animal experimentation. 
 
2.3. Ag and ZnO NPs suspensions preparation 
Concentration (100 mg/kg) of Ag NPs and ZnO NPs suspensions were prepared with deionized distilled water 
. The two suspensions were homogenized by vortex for 20 sec. , then exposed to probe ultrasound sonication 
from Soniprep 150 MES -UK (pulsed mode of 1min operation and 30 sec.  stopping ) in ice bath for 60 min 
[18], the prepared suspensions were immediately exposed to mice with single intraperitoneal injection. 
 
2.4. Experimental desigin  
Three groups of male albino mice with average weight 25±2 gm used for kinetic study , each group contain 34 
mice , first group intraperitoneally injected  with single dose of 100 mg/kg Ag NPs , the same dose of ZnO 
NPs for the second group , the third group was control. Samples of 1 ml blood, and 0.25-0.5 gm of organs 
tissues including (liver, spleen, kidney, intestine, brain, testis, lung, heart) collected from two mice at specific 
time points after injection (5, 10,15, 30, 60 min, 2, 4, 6, 24 h, 2, 4, 7, 9, 11, 14, 18 d ) and kept in -20 Cº until 
prepared for digestion. Feces and urine samples  collected from each group daily.  
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2.5. Ag and ZnO NPs quantitative analysis 
Sub samples 0.25-0.5 gm of  tissue (liver, spleen, kidney, intestine, brain, testis, lung, heart), 1ml of whole 
blood, urine, and 1gm feces samples digest individually using microwave digestion system  from Milestone – 
Italy as described in  [19],[20] using 9 ml of 68-72% nitric acid  HNO3, 1ml of 37% hydrochloric acid HCl, 
and 2 ml of 30% hydrogen peroxide H2O2, the digested samples diluted to 25 ml using distilled water. The 
concentration of silver and zinc detect in each sample using flame or flameless atomic absorption 
spectrophotometer (AAS) from Shimadzu- Japan. 
 
2.6. Kinetic analysis 
The kinetic analysis was performed using a non compartmental model . The bio kinetic parameters including 
maximum concentration (C max), Time to achieve maximum concentration (T max), Half-life of absorption 
(T1/2 Abs) , Half-life of Elimination (T1/2 Elem) calculated using the equation  T 1/2 = 0.693/ k , were the 
elimination rate constant  (K Elem) estimated using the formula k = -2.303 × ((log conc.2- log conc.1)/(time2-
time1)) , Clearance rate (CL)  = K × Vd , and apparent Volume of distribution (Vd) was determined from the 
intercept of the curve. V d = Dose/Intercept as described by [21]. 
 
2.7. Statistical analysis 
The results are presented as the mean ± standard error of means (SE) . Analysis of variance (ANOVA) and 
least significant difference (LSD) were used to explain the differences between means over time points  in 
feces and urine samples at (p≤0.05). 
 
3. Results and descussion  
3.1. Characterization of Ag and ZnO NPs 
According to the granularity distribution chart , the average diameter for Ag and ZnO NPs samples were 24.52 
nm , 25.16 nm respectively with spherical shape determined for the two types of NPs using  AFM (Figure 1) 
 
 
Figure 1. Characteristics of Ag and ZnO NPS  , granularity distribution chart (left) for AgNPs  (A) and  ZnO 
NPs  (B) , spherical shape using AFM (right) for Ag NPs (C) and ZnO NPs (D). 
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3.2. Ag and ZnO NPs absorption 
Blood concentrations analysis against time course after single dose administration of Ag NPs and ZnO NPs 
was efficient method for evaluate the amount of absorption and quantitative the availability , and helps in 
evaluation the amount of distribution  and elimination steps [13]. Highly significant difference (p≤0.05) in 
blood silver and Zn concentrations were illustrated over different time points (Fig 2 , table 1). The 
concentrations elevated within first few minutes followed  injection  with absorption half life  (T 1/2 Abs) of  
26.32 ± 0.57 min and 14.30±0.00 min  for Ag and Zn respectively , and  recording maximum concentration C 
max. with 57.50±2.50 µg/ml , 95±0.00 µg/ml after 1 h and 30 min respectively which indicate the shorter 
needed  time for ZnO  absorption  in versus  with Ag NPs by the effect of the low molecular weight of zinc, 
and the effect of lower apparent volume of distribution (Vd) compared with silver  by which ZnO NPs could 
quickly reach distribution equilibrium between blood and tissues [22]. Lower value of maximum 
concentration detected in blood referred to silver compared with zinc which may caused by molecular weight 
variation [24], the probable aggregations of Ag NPs as the postponement in the peritoneal cavity leading to 
increase the surface area [23] and  reduce the amount of silver that can pass through peritoneal membrane , in 
addition to and amount of generated ions [21], [25] and some considerable effects like lymphatic drainage , 
peritoneal permeability , and particle charge [26] , [27] .  
The results of current study approach with those of  previous one carried out  by  [29] showed the elevation of 
blood zinc level after 30 min. of intraperitoneal injected with 2.5g/kg ZnO NPs with >100 nm in diameter,  the 
peak point recorded after 6 h , then kept with equilibrator scale at 72 h point . In the current study blood zinc 
concentrations need less time to reach their peak point as the effect of smaller particle size and lower 
concentration that play an important role in peritoneal particokinetic . Shorter half life of elimination  (T1/2 
Elem) recorded for zinc oxide NPs 2.38 ±0.08 d from blood compared with silver 8.39 ±0.23 d  which 
considered long and suggested that Ag NPs can not removed from the body in short time  (table 2) , this slow 
elimination manner with low clearance rate (Cl) of 0.43 ±0.03 mg/d.kg  compared with higher recorded one 
with ZnO NPs 0.87 ±0.03 mg/d.kg explained by formation silver protein complexes specially with sulfhydryl 
containing proteins as the high affinity of silver for sulfur group [14],[28] , also the insoluble part of two types 
of NPs may involved . The calculated apparent volume of distribution (Vd)  were  5.16 ±0.25 l/kg (129.00 
±6.15 ml/25 gm)  and 2.99 ±0.02 l/kg (74.75 ±0.56 ml/25gm) for Ag and ZnO NPs respectively , with taking 
into consideration the total body fluid  volume  was 15 ml in the maximum for mouse weighted 25 gm  [15] , 
smaller volume of distribution of ZnO NPs illustrated the shorter needed time for distribution equilibrium  
[21] . It is worth to mention that the resulted values of kinetic parametersb of current study should not be 
compared with parameters in the other studies as the differentr mathematical models and animals weret used 
in the currents study. 
 
 
Figure 2. Silver (A) and Zinc (B) concentrations means in blood (µg/ml) over time followed single 
intraperitoneal (ip) injection with 100 mg/kg Ag and ZnO NPs after subtraction of the basal zinc level in the 
control group  , no silver detected in control group . 
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Table 1.  Ag and Zn means concentration(µg/ml) ± ESM in blood over time points after single intraperitoneal 
injection with 100 mg/kg Ag and ZnO NPs 
 
3.3. Ag and ZnO NPs distribution 
Regardless the route  of administration , nanoparticles may become available systematically and start potential 
interaction with different portions in plasma , blood contents  , and coagulation factors [30], this special 
interaction have important influence on further steps of distribution addition to nano excretion [31]. Figurs 3 
and 4 ,Tables 3 and 4 showed the distribution profile of Ag and ZnO NPs after single intraperitoneal injected 
dose of 100 mg/Kg . With an overview, Ag and Zn were distributed to all  studied organs. The  highest levels 
of silver and zinc showed after 60 and 30 min of injection respectively with the same manner with their levels 
in blood depending in their speed on some factors starting from the half life of absorption  which illustrated by 
increasing retention time of Ag NPs in peritoneal cavity compared with ZnO NPs by the effect of high 
molecular weight as discussed before and the amount of ions released from each kind of  nnanoparticles [26]. 
At time period between 1 h to 1 day the translocation appeared to began in different studded organs which 
may referred to the redistribution of monocytes with remaining in spleen as a reservoir [32] where  silver and 
zinc in particulate, ionic, or complex binding forms may be trans located from the initial uptake tissues to 
other parts of the body through the circulatory system [33]-[36] . After time point of 1-2 days gradual 
dropping were became obvious for both of Ag and Zn concentrations in various studied organs with faster rate 
for Zn as larger clearance rate which recorded for ZnO NPs in blood. Equilibrium become clear after 7 days 
for Ag and not quite cleared for  Zn concentrations . 
 Liver and spleen  which have the dominant  role in immune system [37], hold more nanoparticles pending 
systematic inflammation that led to shorthand retention of nanoparticles by other organs [38] , and their 
clearing  role by the interaction of itself protein effectively with nanoparticles with altering the antigenicity 
and inducing the autoimmune responses, resulting complex of nanoparticle- protein  that can facilitate 
dendritic cells antigen up taking [39]. But as effect of masses different between liver and spleen which have 
smaller one [40] , making spleen have grater accumulation per unit of mass specially during the first hour after 
injection . Interesting high concentrations of Zn were observed in intestine specially at early time of injection 
(10 min-1 h) which may be related to the direct absorption of ZnO NPs  that resides initially  in the visceral 
tissues surrounding area  from intrperitoneal cavity to intestine [41] , in addition to excreted nanoparticles 
ZnO NPs experimental group
ZnO NPs
(100mg/kg) (100 mg/kg)
5 min 0.00 ± 0.00 15.00 ± 0.00 e 5.00 ± 0.00 a 28.75 ± 1.53 f
10 min 0.00 ± 0.00 21.25 ± 1.02 f 5.00 ± 0.00 a 32.50 ± 1.02 h
15 min 0.00 ± 0.00 25.00 ± 0.00 g 5.00 ± 0.51 a 50.63 ± 0.51 j
30 min 0.00 ± 0.00 28.75 ± 1.02 h 5.31 ± 0.26 a 95.00 ± 0.00 k
60 min 0.00 ± 0.00 57.50 ± 2.04 j 5.31 ± 0.26 a 7.50 ± 0.00 b
2 h 0.00 ± 0.00 7.88 ± 0.31
d
5.31 ± 0.26
a
31.25 ± 0.00
g
3 h 0.00 ± 0.00 3.00 ± 0.00 b c 5.00 ± 0.00 a 51.25 ± 0.00 j
4 h 0.00 ± 0.00 4.63 ± 0.31 c 5.00 ± 0.00 a 37.19 ± 0.26 i
6 h 0.00 ± 0.00 22.50 ± 2.04 f 5.00 ± 0.51 a 3.75 ± 0.51 a
1d 0.00 ± 0.00 37.50 ± 2.04 i 5.00 ± 0.00 a 20.63 ± 0.51 e
2 d 0.00 ± 0.00 1.00 ± 0.03 a 5.00 ± 0.51 a 13.44 ± 0.51 d
4 d 0.00 ± 0.00 1.46 ± 0.03 a b 5.00 ± 0.00 a 10.94 ± 0.26 c
7 d 0.00 ± 0.00 1.13 ± 0.03 a b 5.31 ± 0.26 a 10.63 ± 0.00 c
9 d 0.00 ± 0.00 0.54 ± 0.03 a 5.00 ± 0.00 a 10.63 ± 0.26 c
11 d 0.00 ± 0.00 0.38 ± 0.01 a 5.00 ± 0.00 a 7.81 ± 0.26 b
14 d 0.00 ± 0.00 0.38 ± 0.01 a 5.00 ± 0.00 a 7.81 ± 0.26 b
18 d 0.00 ± 0.00 0.38 ± 0.01 a 5.00 ± 0.00 a 7.81 ± 0.26 b
LSD 1.90 0.53 1.03
All data expressed with mean ± standard error of means (SEM), simillar small letters means no significant difference 
between means values on p<0.05   
Control
Ag NPs
Control
Ag NPs experimental group 
Time
dose C Max. T Max. T1/2 Abs. Last T1/2 Elem. Clerance k Elem. Apparent Vd
mg/kg µg/ml min. min. d l/kg.d 1/d l.kg
Ag NPs 100 57.50 ±2.50 60.00 ± 0.00 26.32 ± 0.57 8.39 ±0.23 0.43 ±0.03 0.08 ±0.00 5.16 ±0.25
ZnO NPs 100 95.0 ±0.00 30.00 ±0.00 14.30 ±0.00 2.38 ±0.08 0.87 ±0.03 0.29 ±0.00 2.99 ±0.02
Table 2.  Ag and ZnO NPs blood kinetic parameters means ± ESM after single intraperitoneal injection 
with 100 mg/kg Ag and ZnO NPs 
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from the liver via the biliary pathway [42]. In lung  a considerable concentration of Ag and Zn were noted in 
this study which confirmed the translocation [43], also redistribution of nanoparticles over time which 
indicated before by Dziendzikowska [44] using TEM  in rat alveolar macrophages after 7 days of intravenous 
injection with 5 mg/kg Ag NPs . The noted concentrations decreased  over time to record their lowest levels 
after 9 days and 11 days for Ag and Zn respectively. This study remarked a considerable Ag and Zn levels in 
brain with 2.26±0.00 µg/gm and 32.81±0.31 µg/gm respectively, these results corroborate the ability of both 
types of nanoparticles to cross the blood brain barrier (BBB) as proved in previous studies of 
[45],[16],[46],[44],[47]. The equilibrium were not well clarified at the end time points specially between 7-18 
days as some rising in Ag and Zn concentrations in brain which may related to improved absorption by 
endothelial cells and as a result facilitate their uptake and translocation through blood vessels wall by process 
of transcytosis  [48]. These results came with those of [44] in increasing silver concentration in brain at the 
end point 28 d of their experiment after single intravenous injection with 5 mg/kg of 20 and 200 nm Ag NPs . 
There is an essential evidence proposing that Ag NPs can pass the blood testis barrier BTB as the occurrence 
of silver in the tissue of  testicles which confirmed by exposing animals to Ag NPs through different routs of 
administration [36],[49],[50] , in current study the maximum concentrations of Ag and ZnO were 9.57 ±0.43 
and 48.45±0.39µg/gm after 60 and 30 min of injection respectively with slow rate of elimination over 
experimental time points. 
 
Figure 3.  Silver  concentrations means (µg/gm) in 
(A) Liver, (B) Spleen, (C) Kidney , (D) Brain, (E) 
Intestine, (F) Testes, (G) Lung, and (H) Heart over 
time following single intraperitoneal injection with 
100 mg/kg Ag NPs. 
Figure 4.  Zinc  concentrations means (µg/gm) in (A) 
Liver, (B)Spleen, (C)Kidney, (D) Brain, (E) Intestine, 
(F) Testes, (G) Lung, and (H) Heart over time 
following single intraperitoneal injection with 100 
mg/kg ZnO NPs. 
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Time
Ag NPs Ag NPs
(100mg/kg) (100 mg/kg) (100mg/kg) (100 mg/kg)
5 min 0.00 ± 0.00 6.00 ± 0.00 a 0.00 ± 0.00 15.74 ± 0.93 b 0.00 ± 0.00 11.09 ± 0.22 c 0.00 ± 0.00 0.54 ± 0.07 d
10 min 0.00 ± 0.00 6.75 ± 0.25 a 0.00 ± 0.00 69.44 ± 0.93 h 0.00 ± 0.00 11.96 ± 0.22 d 0.00 ± 0.00 0.63 ± 0.02 e
15 min 0.00 ± 0.00 11.75 ± 0.25 b 0.00 ± 0.00 147.22 ± 0.93 i 0.00 ± 0.00 12.83 ± 0.22 e 0.00 ± 0.00 0.80 ± 0.02 f
30 min 0.00 ± 0.00 43.52 ± 0.93 e f 0.00 ± 0.00 148.15 ± 1.85 i 0.00 ± 0.00 12.61 ± 0.43 d 0.00 ± 0.00 1.02 ± 0.07 g
60 min 0.00 ± 0.00 60.19 ± 0.93 h 0.00 ± 0.00 193.52 ± 0.93 j 0.00 ± 0.00 41.67 ± 0.93 i 0.00 ± 0.00 2.26 ± 0.00 k
2 h 0.00 ± 0.00 39.81 ± 0.93 d 0.00 ± 0.00 36.11 ± 0.93 g 0.00 ± 0.00 13.89 ± 0.93 f 0.00 ± 0.00 1.75 ± 0.05 j
3 h 0.00 ± 0.00 47.22 ± 0.93 g 0.00 ± 0.00 33.33 ± 1.85 f 0.00 ± 0.00 20.50 ± 0.50 h 0.00 ± 0.00 1.55 ± 0.05 i
4 h 0.00 ± 0.00 40.74 ± 1.85 d e 0.00 ± 0.00 31.48 ± 0.00 e 0.00 ± 0.00 17.50 ± 0.50 g 0.00 ± 0.00 1.40 ± 0.10 h
6 h 0.00 ± 0.00 28.70 ± 0.93
c
0.00 ± 0.00 31.48 ± 1.85
e
0.00 ± 0.00 2.57 ± 0.00
ab
0.00 ± 0.00 0.44 ± 0.04
c
1d 0.00 ± 0.00 46.43 ± 1.19 f g 0.00 ± 0.00 21.30 ± 0.93 d 0.00 ± 0.00 3.14 ± 0.14 b 0.00 ± 0.00 0.38 ± 0.05 c
2 d 0.00 ± 0.00 81.25 ± 2.08
i
0.00 ± 0.00 19.44 ± 0.93
c
0.00 ± 0.00 2.21 ± 0.07
a
0.00 ± 0.00 0.22 ± 0.02
a
4 d 0.00 ± 0.00 45.83 ± 4.17
f
0.00 ± 0.00 19.44 ± 0.93
c
0.00 ± 0.00 2.14 ± 0.14
a
0.00 ± 0.00 0.20 ± 0.01
a
7 d 0.00 ± 0.00 27.50 ± 2.50
c
0.00 ± 0.00 0.07 ± 0.00
a
0.00 ± 0.00 2.21 ± 0.07
a
0.00 ± 0.00 0.28 ± 0.01
b
9 d 0.00 ± 0.00 27.50 ± 1.67 c 0.00 ± 0.00 0.07 ± 0.00 a 0.00 ± 0.00 2.21 ± 0.07 a 0.00 ± 0.00 0.26 ± 0.01 a b
11 d 0.00 ± 0.00 27.29 ± 2.29 c 0.00 ± 0.00 0.06 ± 0.00 a 0.00 ± 0.00 2.21 ± 0.07 a 0.00 ± 0.00 0.23 ± 0.01 a
14 d 0.00 ± 0.00 27.08 ± 2.08 c 0.00 ± 0.00 0.06 ± 0.00 a 0.00 ± 0.00 2.21 ± 0.07 a 0.00 ± 0.00 0.21 ± 0.01 a
18 d 0.00 ± 0.00 27.08 ± 2.08 c 0.00 ± 0.00 0.06 ± 0.00 a 0.00 ± 0.00 2.21 ± 0.07 a 0.00 ± 0.00 0.21 ± 0.01 a
LSD NO 3.00 NO 1.70 NO 0.70 NO 0.07
Time
Control (100mg/kg) Control (100 mg/kg) Control (100mg/kg) Control (100 mg/kg)
5 min 0.00 ± 0.00 9.25 ± 0.75 b 0.00 ± 0.00 4.57 ± 0.22 c d 0.00 ± 0.00 6.52 ± 0.43 e 0.00 ± 0.00 4.78 ± 0.00 f
10 min 0.00 ± 0.00 11.50 ± 0.50 c 0.00 ± 0.00 4.57 ± 0.22 c d 0.00 ± 0.00 7.61 ± 0.22 f 0.00 ± 0.00 5.87 ± 0.22 g
15 min 0.00 ± 0.00 18.75 ± 0.75 e 0.00 ± 0.00 5.00 ± 0.22 d 0.00 ± 0.00 9.78 ± 0.22 h 0.00 ± 0.00 6.96 ± 0.00 h
30 min 0.00 ± 0.00 38.89 ± 1.85 h 0.00 ± 0.00 7.39 ± 0.43 f 0.00 ± 0.00 10.22 ± 0.65 h 0.00 ± 0.00 8.26 ± 0.00 i
60 min 0.00 ± 0.00 86.11 ± 0.93 i 0.00 ± 0.00 9.57 ± 0.43 h 0.00 ± 0.00 12.61 ± 0.00 j 0.00 ± 0.00 9.15 ± 0.02 j
2 h 0.00 ± 0.00 17.50 ± 0.50 e 0.00 ± 0.00 8.46 ± 0.77 g 0.00 ± 0.00 11.15 ± 0.38 i 0.00 ± 0.00 6.92 ± 0.00 h
3 h 0.00 ± 0.00 11.50 ± 0.50 c 0.00 ± 0.00 6.54 ± 0.38 e 0.00 ± 0.00 8.08 ± 0.38 g 0.00 ± 0.00 6.92 ± 0.00 h
4 h 0.00 ± 0.00 14.00 ± 0.00 d 0.00 ± 0.00 4.62 ± 0.38 c d 0.00 ± 0.00 5.50 ± 0.00 d 0.00 ± 0.00 6.75 ± 0.75 h
6 h 0.00 ± 0.00 27.00 ± 3.00 f 0.00 ± 0.00 4.38 ± 0.38 c 0.00 ± 0.00 3.95 ± 0.47 c 0.00 ± 0.00 2.91 ± 0.12 d
1d 0.00 ± 0.00 35.00 ± 3.00 g 0.00 ± 0.00 4.88 ± 0.38 c d 0.00 ± 0.00 4.30 ± 0.35 c 0.00 ± 0.00 3.26 ± 0.23 e
2 d 0.00 ± 0.00 19.00 ± 1.00 e 0.00 ± 0.00 2.93 ± 0.07 b 0.00 ± 0.00 2.43 ± 0.00 b 0.00 ± 0.00 2.36 ± 0.07 c
4 d 0.00 ± 0.00 2.29 ± 0.14 a 0.00 ± 0.00 2.57 ± 0.14 b 0.00 ± 0.00 2.43 ± 0.14 b 0.00 ± 0.00 2.29 ± 0.00 c
7 d 0.00 ± 0.00 2.21 ± 0.07 a 0.00 ± 0.00 3.07 ± 0.07 b 0.00 ± 0.00 2.21 ± 0.07 b 0.00 ± 0.00 2.14 ± 0.00 c
9 d 0.00 ± 0.00 2.07 ± 0.07 a 0.00 ± 0.00 0.97 ± 0.03 a 0.00 ± 0.00 0.89 ± 0.04 a 0.00 ± 0.00 1.07 ± 0.07 b
11 d 0.00 ± 0.00 1.21 ± 0.07 a 0.00 ± 0.00 1.07 ± 0.07 a 0.00 ± 0.00 0.75 ± 0.04 a 0.00 ± 0.00 0.68 ± 0.04 a
14 d 0.00 ± 0.00 1.21 ± 0.07 a 0.00 ± 0.00 1.17 ± 0.03 a 0.00 ± 0.00 0.75 ± 0.04 a 0.00 ± 0.00 0.61 ± 0.04 a
18 d 0.00 ± 0.00 1.21 ± 0.07 a 0.00 ± 0.00 1.37 ± 0.03 a 0.00 ± 0.00 0.75 ± 0.04 a 0.00 ± 0.00 0.64 ± 0.07 a
LSD NO 2.03 NO 0.53 NO 0.47 NO 0.34
All data expressed with mean ± standard error of means (SEM), simillar small letters means no significant difference between means values on p≤0.05
Ag NPs Ag NPs Ag NPs Ag NPs
Small intestine Testes Lung Heart
Spleen
Control Control Control Control
BrainLiver Kidney
Ag NPs Ag NPs
Table 3. Silver concentrations means (µg/gm) ±SEM in liver, spleen, kidney, brain, intestine, testes, lung, heart 
over experimental time points following single intraperitoneal injection with 100 mg/kg Ag NPs. 
 
Time
ZnO NPs ZnO NPs
(100mg/kg) (100 mg/kg) (100mg/kg) (100 mg/kg)
5 min 14.39 ± 0.24 a 22.22 ± 1.85 a 4.88 ± 0.49 a 52.86 ± 0.48 h 9.02 ± 0.24 a 18.57 ± 0.48 a 10.00 ± 0.24 a 13.84 ± 0.45 b
10 min 14.15 ± 0.49 a 36.19 ± 0.95 c 4.63 ± 0.73 a 130.95 ± 2.38 k 8.78 ± 0.49 a 27.14 ± 0.48 f 10.00 ± 0.24 a 14.23 ± 0.38 b c
15 min 14.39 ± 0.24 a 84.29 ± 0.48 h 4.63 ± 0.24 a 148.57 ± 0.95 l 9.02 ± 0.24 a 79.52 ± 0.48 k 10.00 ± 0.24 a 21.92 ± 0.38 g 
30 min 14.39 ± 0.24 a 139.05 ± 0.95 k 4.88 ± 0.49 a 198.10 ± 0.95 m 9.27 ± 0.49 a 89.52 ± 0.95 l 10.00 ± 0.24 a 32.81 ± 0.31 k
60 min 14.39 ± 0.24 a 35.24 ± 0.95 c 4.63 ± 0.73 a 130.00 ± 2.38 k 9.02 ± 0.24 a 26.19 ± 0.48 e f 10.00 ± 0.24 a 16.09 ± 0.43 d
2 h 14.15 ± 0.49 a 34.35 ± 0.43 b c 4.63 ± 0.73 a 25.22 ± 0.00 d 9.27 ± 0.49 a 24.78 ± 0.43 d e 10.00 ± 0.24 a 16.52 ± 0.87 d e
3 h 14.39 ± 0.24 a 56.09 ± 0.43 f 4.63 ± 1.22 a 116.52 ± 0.87 j 9.02 ± 0.24 a 38.26 ± 0.00 i 10.00 ± 0.24 a 17.39 ± 0.00 e 
4 h 14.15 ± 0.49 a 67.83 ± 0.87 g 4.88 ± 0.49 a 106.96 ± 0.00 i 8.78 ± 0.49 a 30.87 ± 0.43 h 10.00 ± 0.24 a 23.48 ± 0.00 h
6 h 14.15 ± 0.49 a 52.53 ± 2.02 e 4.63 ± 0.73 a 33.33 ± 1.01 e 9.02 ± 0.24 a 39.39 ± 1.01 i 10.00 ± 0.24 a 27.50 ± 0.50 i
1d 14.15 ± 0.49 a 87.88 ± 1.01 i 4.88 ± 0.98 a 47.47 ± 1.01 g 9.51 ± 0.24 a 45.96 ± 1.52 j 10.00 ± 0.24 a 29.00 ± 1.00 j
2 d 14.39 ± 0.24 a 93.89 ± 0.56 j 4.63 ± 0.24 a 45.70 ± 0.54 f 9.02 ± 0.24 a 29.03 ± 2.15 g 10.00 ± 0.24 a 21.67 ± 0.56 g
4 d 14.39 ± 0.24 a 43.33 ± 4.44 d 4.63 ± 0.73 a 18.82 ± 0.54 b c 9.27 ± 0.49 a 24.19 ± 0.54 c d 10.00 ± 0.24 a 11.67 ± 0.56 a
7 d 14.15 ± 0.49 a 32.78 ± 0.56 b 4.63 ± 0.24 a 17.74 ± 0.54 b 9.02 ± 0.24 a 23.12 ± 0.54 b c 10.00 ± 0.24 a 15.00 ± 0.56 c 
9 d 14.39 ± 0.24 a 32.78 ± 0.56 b 4.88 ± 0.98 a 19.89 ± 0.54 c 8.78 ± 0.49 a 22.58 ± 0.00 b 10.00 ± 0.24 a 16.11 ± 0.56 d
11 d 14.15 ± 0.49 a 32.78 ± 0.56 b 4.88 ± 0.49 a 12.37 ± 0.54 a 9.02 ± 0.24 a 22.58 ± 1.08 b 10.00 ± 0.24 a 17.22 ± 0.56 e
14 d 14.39 ± 0.24 a 32.78 ± 0.56 b 4.63 ± 0.73 a 11.29 ± 0.54 a 9.02 ± 0.24 a 22.58 ± 1.08 b 10.00 ± 0.24 a 18.33 ± 0.56 f
18 d 14.39 ± 0.24 a 32.78 ± 0.56 b 4.88 ± 0.49 a 11.83 ± 0.00 a 9.02 ± 0.24 a 22.58 ± 0.00 b 10.00 ± 0.24 a 21.67 ± 0.56 g
LSD 0.61 2.36 1.10 1.71 0.81 1.46 0.40 0.90
Time
Control (100mg/kg) Control (100 mg/kg) Control (100mg/kg) Control (100 mg/kg)
5 min 10.73 ± 0.00 a 15.24 ± 0.95 a 5.61 ± 0.24 a 23.33 ± 0.48 e 5.12 ± 0.24 a 22.77 ± 0.45 d 5.61 ± 0.24 a 25.00 ± 0.00 g
10 min 10.24 ± 0.49 a 103.81 ± 0.00 h 5.37 ± 0.49 a 28.13 ± 0.45 g 5.37 ± 0.49 a 34.76 ± 0.48 i 5.85 ± 0.49 a 32.38 ± 0.95 i
15 min 10.85 ± 0.37 a 196.19 ± 0.95 i 5.61 ± 0.24 a 45.34 ± 0.62 i 5.61 ± 0.24 a 78.68 ± 1.16 k 5.61 ± 0.24 a 75.58 ± 0.39 j
30 min 10.73 ± 0.49 a 411.90 ± 0.48 j 5.61 ± 0.73 a 48.45 ± 0.39 j 5.12 ± 0.24 a 40.06 ± 0.31 j 5.85 ± 0.49 a 23.29 ± 0.93 e
60 min 10.85 ± 0.12 a 196.19 ± 0.95 i 5.61 ± 0.24 a 22.38 ± 0.48 d 5.37 ± 0.49 a 25.24 ± 0.48 e 6.10 ± 0.24 a 32.38 ± 0.95 i
2 h 10.49 ± 0.24 a 31.30 ± 0.87 c 5.61 ± 0.73 a 25.65 ± 0.43 f 5.61 ± 0.24 a 15.65 ± 0.00 b 6.10 ± 0.24 a 21.30 ± 0.43 d
3 h 10.98 ± 0.24 a 53.48 ± 0.43 e 5.61 ± 0.24 a 24.78 ± 0.43 f 5.12 ± 0.24 a 13.04 ± 0.87 a 5.61 ± 0.73 a 23.91 ± 0.43 e f
4 h 10.73 ± 0.49 a 99.57 ± 0.43 g 5.37 ± 0.49 a 22.61 ± 0.00 d e 5.85 ± 0.49 a 30.00 ± 0.43 g 5.61 ± 0.24 a 30.43 ± 0.00 h
6 h 10.24 ± 0.49 a 32.32 ± 5.05 c 5.85 ± 0.49 a 32.50 ± 0.50 h 5.61 ± 0.24 a 31.50 ± 1.50 h 5.85 ± 0.49 a 24.50 ± 0.50 f g
1d 10.85 ± 0.85 a 90.40 ± 0.51 f 5.37 ± 0.49 a 22.00 ± 2.00 c d 5.12 ± 0.24 a 27.00 ± 1.00 f 5.85 ± 0.49 a 19.50 ± 0.50 c
2 d 10.73 ± 0.49 a 89.78 ± 0.54 f 5.61 ± 0.24 a 20.97 ± 0.54 c 5.61 ± 0.24 a 19.89 ± 0.54 c 5.61 ± 0.73 a 17.74 ± 0.54 b
4 d 10.24 ± 0.49 a 34.95 ± 0.54 d 6.10 ± 0.24 a 16.67 ± 0.54 a 5.85 ± 0.49 a 19.89 ± 0.54 c 5.85 ± 0.49 a 17.74 ± 0.54 b
7 d 10.49 ± 0.24 a 25.27 ± 0.54 b 5.61 ± 0.24 a 18.82 ± 0.54 b 5.37 ± 0.49 a 19.89 ± 0.54 c 5.61 ± 0.24 a 17.74 ± 0.54 b
9 d 10.49 ± 0.24 a 25.27 ± 0.54 b 5.37 ± 0.49 a 18.82 ± 0.54 b 5.61 ± 0.73 a 15.59 ± 0.54 b 5.37 ± 0.49 a 15.59 ± 0.54 a
11 d 10.49 ± 0.24 a 25.27 ± 0.54 b 5.85 ± 0.49 a 15.59 ± 0.54 a 5.12 ± 0.24 a 15.59 ± 0.54 b 5.85 ± 0.49 a 15.59 ± 0.54 a
14 d 10.49 ± 0.00 a 25.27 ± 0.54 b 5.37 ± 0.49 a 15.59 ± 0.54 a 5.37 ± 0.49 a 15.59 ± 0.54 b 5.37 ± 0.49 a 15.59 ± 0.54 a
18 d 10.59 ± 0.15 a 25.27 ± 0.54 b 5.61 ± 0.24 a 15.59 ± 0.54 a 5.61 ± 0.24 a 15.59 ± 0.54 b 5.37 ± 0.49 a 15.59 ± 0.54 a
LSD 0.66 2.28 0.74 1.13 0.78 1.17 0.82 0.97
Al l  data  expressed with mean ± standard error of means (SEM), simillar small letters means no significant difference between means values on p≤0.05
Small intestine Testes Lung Heart
Liver Spleen Kidney Brain
Control
ZnO NPs ZnO NPs ZnO NPs ZnO NPs
ZnO NPs ZnO NPs
Control Control Control
Table 4. Zinc concentrations means (µg/gm) ±SEM in liver, spleen, kidney, brain, intestine, testes, lung and 
heart over experimental time points following single intraperitoneal injection with 100 mg/kg Ag NPs. 
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3.4. Ag and ZnO NPs excreation  
The excretion kinetics of Ag and  ZnO  nanoparticles were evaluated after 1day of intraperitoneal injection by 
measuring daily silver and zinc concentrations in feces and urine which collected over 18 days . A 
considerable mean values of silver and zinc levels in feces and urine were noted after  one day of  injection 
(Figure 5, table 5) . with 131.67 ± 1.36 µg/gm in feces obverse to 2.89 ±0.03 µg/ml in urine samples for silver, 
214.00±1.63 µg/gm and 15.00±0.00 µg/ml for Zinc in feces and urine respectively , these averages decreased 
with highly statistical significant difference (p≤0.05) reaching to the lowest concentrations values after 13 
days and stand on 18.33 ±1.36 µg/gm in feces sample and extremely low concentration in urine samples with 
0.54±0.03 µg/ml , this profile of reducing concentrations over days may be refers to silver binding with the 
intestinal surfaces which led to decreasing the concentrations in the feces . Silver excretion percentage via 
urine appeared extremely low  0.8±0.019 % compared with their percentage in feces 33±0.17%  (Table 5) as 
the excretion of Ag NPs via renal system could not be the main path of elimination , furthermore small 
amount of Ag detected in feces pointed that Ag NPs were excreted slowly by the biliary pathway  or deposited 
in different organs over long time [51].These results approached to the demonstrations of  [17] in the 
recording the fecal excretion percentage of 35.87± 9.94% , also [35] mentioned  the recovering of 50% of 
silver of infused  dose  in bile of rat after non oral administration. ZnO NPs excretion kinetic take the same 
manner as in Ag NPs with the high percentage of fecal excretion 83± 0.180% against urinary one with 
7.5±0.020% . As mentioned with silver, the highest excretion averages of zinc in feces and urine samples were 
recorded after one day of injection (214±1.63µg/gm, 15±0.00 µg/ml) respectively, and decrees with remark 
significant differences (p≤0.05) to record their lowest levels in feces and urine samples after 16 days of 
injection with 65.5±0.41µg/gm, 6.5±0.41µg/ml respectively (Figure 4). These high scales of Zn in feces 
compared with their equivalents in urine referred to vastly elimination of ZnO NPs were take placed  by the 
bile into feces [16],[52] which play a crucial roles in the elimination of nanoparticles regardless the factors of 
experimental animal type and their sex, routes of exposure, particulate size and charge [53]. 
 
 
Figure 5. Silver (A,B)  and Zinc (C,D) concentrations means ±SE in feces (µg/gm)  and urine (µg/ml) samples over days 
after single intraperitoneal (ip) injection with 100 mg/kg Ag and ZnO NPs 
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4. Conclusions 
The present study illustrate the kinetic profile of Ag and ZnO NPs followed the intraperitoneal injection with 
same dose of the two type of nano particles in mice which is not demonstrated  in previous study  . In 
summery ZnO NPs need 30 min for absorption into the blood and reaching to all studded organs facing to Ag 
NPs which need 1 h . Ag NPs spend more time for elimination (T1/2 Elem.) with over 8.39 days  compared 
with ZnO NPs as their  lower clearance rate (CL) and higher volume of distribution (Vd) . higher excretion 
percentage recorded with ZnO NPs in feces and less by urine compared with Ag NPs .  
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